As of March 2025, Ferdinand Winter (pictured) has been appointed General Counsel of Ten23 health, a Swiss pharmaceutical contract development and manufacturing organization. Moving from Hansa Biopharma, Sweden, Ferdinand will be responsible for establishing and leading Ten23 health’s legal, compliance, and IP practices. In particular this newly created role will entail the creation of new […]
Karen Hale (pictured) is the new Chief Legal and Compliance Officer for Novartis, effective April 14, 2025. Following the new appointment, Hale will continue to report to Vas Narasimhan, CEO of Novartis, and remain on the Executive
Forty percent of European Chief Legal Officers (CLOs) have reported increased costs due to internal investigations, 11% higher than the global average of 29%, according to the 2025 ACC Chief Legal Officers Survey. The report, released by the
Alexander Toller (pictured) has been appointed first-ever general counsel of Rolex. Starting on January 1, the former partner at Lalive for nearly three decades, will take care of the legal needs of the luxury watches brand
Corinne Russi (pictured) has been appointed as SIG Group legal counsel, as indicated on her LinkedIn profile. Corinne Russi’s career path Corinne Russi is a legal professional with extensive experience in corporate law, M&
Lukas Studer, general counsel corporate and M&A, is appointed group general counsel at Holcim, effective 1 November 2024. He succeeds Mathias Gaertner, who will be joining ABB as as new General Counsel and Company Secretary
On July 1st 2024, Wolfgang Wienand (pictured) joins Lonza as its new CEO. Wolfgang Wienand’s career path According to his LinkedIn profile, Wienand was vice president strategy & business development at Evonik – where he worked
Stéphanie Fougou (pictured) is the new president of the European Company Lawyers Association (ECLA). Never before, in its 41-year history, has ECLA been chaired by a woman. Stéphanie Fougou and ECLA Fougou is
Boris Zaïtra (pictured), currently head of group business development, will be appointed as head of corporate business development, effective 1 july 2024. James Sabry, head of Roche Pharma Partnering, will be retiring after fourteen years in
Bär & Karrer and Willkie Farr & Gallagher advised PAI Partners (PAI) on the acquisition of Vamed Group’s rehabilitation business (VAMED) from Fresenius, advised by NKF and Latham & Watkins. PAI will become
